Drug Prices: U.S. Patients Not First
July 2, 2018 | Vivian Ho, Hagop M. Kantarjian

Table of Contents
Author(s)
Vivian Ho
James A. Baker III Institute Chair in Health EconomicsHagop M. Kantarjian
Nonresident Fellow in Health PolicyThe Trump administration's "American Patients First" plan is a green light for drug companies to continue their unfettered pricing schemes write the authors, who offer three steps to lower prescription drug prices in the U.S. The Hill: https://bit.ly/2KJuQt7